Controlling chronic noncancer pain in an era of opioid misuse

Area of Science:

• Pharmacology
• Public Health Policy
• Pain Management

Background:

• The opioid crisis necessitates strategies to curb abuse and diversion.
• Risk Evaluation and Mitigation Strategies (REMS) are regulatory tools designed to manage known or potential serious risks associated with a drug.
• Concerns exist regarding the unintended consequences of REMS on legitimate pain management.

Purpose of the Study:

• To assess the effectiveness of the new federal Risk Evaluation and Mitigation Strategy (REMS) in preventing prescription opioid abuse.
• To investigate whether the implementation of this REMS program may inadvertently restrict access to opioid analgesics for patients with legitimate pain.
• To analyze the balance between risk mitigation and therapeutic necessity in opioid pharmacotherapy.

Main Methods:

• Review of regulatory documents and policy guidelines pertaining to the federal opioid REMS.
• Analysis of prescribing data and opioid utilization trends pre- and post-REMS implementation.
• Examination of patient-reported outcomes and physician surveys regarding pain management experiences.

Main Results:

• Preliminary data suggests a potential decrease in certain types of opioid abuse indicators.
• However, a notable trend indicates a possible reduction in opioid prescriptions for chronic pain conditions.
• Patient-reported data highlights challenges in accessing adequate pain relief under the new REMS framework.

Conclusions:

• The federal opioid REMS may show promise in curbing specific abuse patterns.
• There is a significant concern that the strategy could impede access to essential pain relief for legitimate patients.
• Further research and potential adjustments to the REMS are warranted to ensure both safety and effective pain management.